Research in 'Prostatitis Syndromes':
The Use of Alfuzosin (a New α(1)-Receptor-Blocking Agent) in Patients Mainly Presenting with Micturition Complaints of an Irritative Nature and Confirmed Urodynamic Abnormalities

Rosette, Jean J.M.C.H. de la; Karthaus, H. F. M.; Kerrebroeck, Philip E. V. A. Van; Boo, Theo de; Debruyne, F.M.J.

doi:10.1159/000474760

Cited by 56 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Encouraging results were reported for alpha 1 blockers in trials evaluating: terazosin [44,45] , doxazosin [46] , and alfuzosin [43] ( table 3 ). These observations were extended in other uncontrolled investigations of multimodal programs incorporating alpha blockers in various combinations with antibiotics, anti-inflammatory drugs, prostatic massage, anti-inflammatory phytotherapy, and neuromuscular agents [41,[47][48][49] .…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Role of Alpha Blocker Therapy

et al. 2007

View full text Add to dashboard Cite

Introduction: This article reviews the rationale and data supporting alpha blocker therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), the most common and difficult prostatitis syndrome. Methods: Systematic review identified ten clinical trials evaluating alpha blocker therapy for patients with CP/CPPS, including five open-label or small prospective studies and five double-blinded and placebo-controlled clinical trials. Results: Encouraging results in uncontrolled and small clinical trials led to the development of reasonably powered, double-blinded, placebo-controlled, randomized clinical trials evaluating terazosin, doxazosin, tamsulosin, and alfuzosin. Conclusions: Current data suggest that treatment-naïve and/or newly diagnosed patients appear more likely to respond than long-term, chronic refractory patients. Longer courses of treatment (12 weeks to 6 months) appear superior to shorter courses, and less selective agents appear superior to more selective alpha₁ blockers. These observations outline important questions that must be answered to define optimal treatment strategies for patients with CP/CPPS.

show abstract

Section: Reviewmentioning

confidence: 99%

“…The development of more selective alpha 1 agents with fewer side effects led to uncontrolled, open-label trials [40][41][42] and some small randomized prospective studies [36,43] . Encouraging results were reported for alpha 1 blockers in trials evaluating: terazosin [44,45] , doxazosin [46] , and alfuzosin [43] ( table 3 ).…”

Section: Reviewmentioning

confidence: 99%

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Role of Alpha Blocker Therapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Some studies do exist that suggest an improvement in the symptoms of patients with "NIH III a/b prostatitis" [22][23][24][25]. Whether this is due to improving outflow performance by blocking the α receptors of the bladder neck and prostate is not known.…”

Section: Prostate Pain Syndromementioning

confidence: 99%

Perineal Pain in Males

Baranowski

2010

Evidence‐Based Chronic Pain Management

View full text Add to dashboard Cite

“…This study became a landmark for conducting further trials of alpha blockers in this disease complex. De la Rosette et al [10] in a double blind placebo controlled trial reported the results of short acting alfuzosin versus placebo in patients with a clinical diagnosis of CP. A statistically signifi cant improvement in the maximum fl ow rate (Q-max) and reduction in symptom score was observed with alfuzosin.…”

Section: A Brief Review Of Clinical Trialsmentioning

confidence: 99%

Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results

Singh

Sinha

2008

Indian J Surg

View full text Add to dashboard Cite

Chronic prostatitis / chronic pelvic pain syndrome (NIH-type II and type III prostatitis) are common cause of chronic pelvic pain. The exact etiology of these entities are unknown. They are associated with varying degree of voiding and sexual dysfunction. Consensus regarding treatment of these pain syndromes is lacking. Review of literature suggest a therapeutic role of alpha adrenergic receptor blockers in the management of NIH-type II and type III prostatitis. A trial of alpha-blocker is reasonably inexpensive and appropriate for most patients suffering from NIH-type III prostatitis and NIH-type II prostatitis. A general consensus is that if a patient agrees to a trial of alphablocker therapy which subsequently shows a good response then it should be continued for at least 6 months for a proper therapeutic effect. This review analyses the role of alphablockers in this disease/syndrome; discusses the possible mechanism of action through which these drugs provide relief and also highlights some of the important trials which have paved way for this particular treatment option in this intriguing disease /syndrome. Keywords Prostate . . Pain . . Adrenergic alpha antagonists . . Chronic prostatitis with chronic pelvic pain syndrome.

show abstract

Research in 'Prostatitis Syndromes': The Use of Alfuzosin (a New α(1)-Receptor-Blocking Agent) in Patients Mainly Presenting with Micturition Complaints of an Irritative Nature and Confirmed Urodynamic Abnormalities

Cited by 56 publications

References 16 publications

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Role of Alpha Blocker Therapy

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Role of Alpha Blocker Therapy

Perineal Pain in Males

Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results

Contact Info

Product

Resources

About